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ABSTRACT
Esophageal squamous cell carcinoma (ESCC) is the most common esophageal 
cancer associated with poor prognosis and additional therapeutic strategies must 
be implemented to optimize ESCC treatment. Meanwhile, the important biologic 
role and potential prognostic and therapeutic implications of a tumors immunologic 
microenvironment (IM) have been recognized in various cancers.
In order to investigate the contexture and the prognostic relevance of the IM 
in ESCC, we immunohistochemically evaluated the extent of overall/intraepithelial 
TILs (CD3+/CD8+) and of PD-1 / PD-L1 expression in a cohort of 125 therapy-naive 
ESCCs, additionally assessing PD-L1 copy number status via fluorescence in-situ 
hybridization.
High intraepithelial CD3+ TILs (CD3ihigh) and high PD-L1 expression on tumor 
cells (PD-L1high) were each significantly associated with improved overall- (OS) 
(CD3+: p = 0.019; PD-L1: p = 0.028), disease specific- (DSS) (CD3+: p = 0.05; PD-
L1: p = 0.006) and disease free survival (DFS) (CD3+: p = 0.009; PD-L1: p < 0.001). 
CD3ihigh- and PD-L1high cases were significantly associated with one another (p < 
0.001). Subgrouping of ESCC revealed decreased OS (p = 0.031), DSS (p = 0.012) 
and DFS (p < 0.001) for CD3ilow/PD-L1low cancers.
Our data not only associate CD3ihigh- and PD-L1high ESCC with a beneficial 
outcome, but also demonstrate PD-L1high- and CD3ihigh status to be closely 
intertwined. Furthermore, our study demarcates a prognostically unfavorable, “non-
immunoreactive” CD3ilow / PD-L1low ESCC-subgroup, potentially forming the basis 
for an immune-based stratification of ESCC.
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INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is 
a substantial cause of cancer-related death worldwide, 
accounting for approximately 80% of esophageal cancers 
[1-6]. ESCC is usually associated with poor patient 
prognosis, with reported 5-year overall survival rates 
varying from 15-40% [2, 4, 7]. Although diagnostic and 
therapeutic advances have led to slight improvements 
in the clinical management and outcome of ESCC [2, 5, 
7], the implementation of additional treatment strategies 
and novel prognostic biomarkers must be expedited to 
optimize ESCC treatment.
The recognition of the immunologic 
microenvironment (IM) of a malignant tumor as a 
potentially powerful biomarker of prognostic and 
therapeutic relevance has led to a resurgence of immune 
based therapy strategies in solid cancers. Firstly, the 
immunologic tumor-host relationship appears to be of 
substantial importance for the carcinogenic process [8, 
9] and especially the extent of CD3+ and CD8+ tumor 
infiltrating lymphocytes (TILs) seems to be of special 
interest for the evaluation of a potential immunogenic 
antitumor response [10-13]. Particularly, intraepithelial 
CD3+ T-cells have been identified as valid prognosticators 
in a variety of adenocarcinomas [14-17]. Secondly, 
immune-checkpoint blockade, especially via inhibition 
of the potent immunoevasive effects of the Programmed 
Death-1 (PD-1) / Programmed Death – Ligand 1 (PD-L1) 
axis, has become a powerful tool of tumor immunotherapy, 
with variable responses in diverse cancer types [18, 19, 20] 
and partially conflicting results regarding the predictive 
value of immunohistochemical PD-L1 expression [18]. 
Furthermore, a recent pan-cancer classification approach 
proposes a model of four different types of tumor 
microenvironments, based on a tumors T-cell infiltration 
and PD-L1 positivity [13]. 
However, in ESCC, data regarding its IM are 
limited and the prognostic value of PD-L1 expression is 
still a matter of debate, as some studies associate PD-L1 
expression with a rather favorable [21, 22] prognosis, 
while others postulate a less favorable [23-25] disease 
course for PD-L1 positive cancers. 
In order to investigate the contexture and possible 
clinicopathological implications of the IM including the 
PD-1 / PD-L1 axis in ESCC, we immunohistochemically 
analyzed the extent and distribution of overall and 
intraepithelial CD3+ / CD8+ TILs as well as PD-1 / PD-
L1 expression in a tumor series of 125 primary resected, 
therapy-naive ESCCs. Additionally, the tumors PD-L1 
copy number status was evaluated through Fluorescence 
in situ Hybridization (FISH).
The questions we addressed focused on (1) 
the specific composition of the IM in ESCC, (2) the 
identification of possible associations of overall and 
intraepithelial TILs with specific clinicopathological and 
survival parameters, (3) the predictive value of PD-L1 
immunohistochemistry in ESCC and (4) the relationship 
of the PD-1 / PD-L1 axis to the IM, particularly focusing 
on potential immunologic ESCC subgroups based on their 
extent of T-cell infiltration and PD-L1 positivity. 
RESULTS
Clinicopathological characteristics
95 of the 125 ESCC patients in our tumor series 
were male (76%), 30 were female (24%). Mean age at 
diagnosis was 60 years (range: 39-83). Rather locally 
advanced cancers (pT2-pT4: 70/125; 56%) and early 
stage carcinomas (pT1: 55/125; 44%) were roughly evenly 
distributed, synchronous lymph node metastases (pN+) 
were detectable in 57 cases (46%) and four cases showed 
synchronous distant metastases (pM1: 3%). According 
to the WHO classification of the digestive system [26], 
most ESCCs were moderately (G2; 49%) or poorly 
differentiated (G3; 46%) with only a minor subset of well 
differentiated tumors (G1; 5%). 53 (42%) patients suffered 
from local and/or distant relapse and 79 (63%) patients 
died during follow up, of which 82% (65/79) were tumor 
specific deaths. Mean follow-up time for patients alive at 
the endpoint of overall survival analysis was 65.09 months 
(Table 1).
Composition of intraepithelial tumor infiltrating 
lymphocytes in ESCC
Intraepithelial CD3+ TIL (CD3i) count was 
heterogeneous showing a wide range from 0-70/100 
(median: 12) tumor cells (TC). 44/125 ESCCs exceeded 
the 66. percentile, harboring >20 CD3is (43%; CD3ihigh), 
while the remaining cancers had <20 CD3is and were 
therefore classified as CD3ilow. 50 tumors (40%) showed 
diffuse CD3i distribution. Intraepithelial CD8+ TIL 
(CD8i) count fluctuated from 0-70/100 TCs (median: 6). 
38 tumors clustered within the upper third and had >13 
CD8is (30%; CD8ihigh). Diffuse CD8is were detectable 
in 40 (32%) cases. Intraepithelial PD-1+ TIL (PD1i) count 
varied from 0-25/100 TCs (median: 3) and 41 cases had a 
high PD1i count of >6 PD1is, exceeding the 66. percentile 
(33%; PD1ihigh) (Table 1, Figure 1). 
Density of tumor infiltrating lymphocytes in the 
whole tumor area
Overall density of CD3+ TILs occupying the whole 
tumor area fluctuated from 1-60% (median: 10%; high 
overall CD3+ TILs: 15%, 83/125). Overall density of 
CD8+ TILs varied from 1-50% (median: 5%; high overall 
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CD8+ TILs: 10%, 48/125), whereas overall PD1+ TILs 
ranged from 0-60% (median: 3%; high overall PD1+ TILs: 
4%, 49/125) (Supplementary Figure 1).
Expression of PD-L1
Immunohistochemically, at least partial membranous 
PD-L1 staining was detectable in 71% of ESCCs (89/125, 
median: 3%), showing a range from 0-90% positive tumor 
cells. 38/125 (30%) cases were classified as PD-L1high 
as their amount of PD-L1 positive TCs exceeded the 66. 
percentile (>10% positive TCs). Weak (34%), intermediate 
(31%) and strong (35%) staining intensities were almost 
evenly distributed among the PD-L1 positive cases. 
PD-L1+ TILs were detectable in 109/125 cases 
(87%) and their density within the whole tumor area 
varied from 0-60% (median: 3%; high overall PD-L1+ 
TILs: 5%, 36/125) (Table 1, Figure 1).
PD-L1 copy number status
Assessment of the PD-L1 copy number status via 
FISH revealed PD-L1 amplifications in 3/125 (2%) and 
PD-L1 deletions in 10/125 (8%) ESCCs. The remaining 
cases displayed PD-L1 disomy (92/125; 74%) or polysomy 
(19/125, 15%) (Table 1, Supplementary Figure 1). 
Subgrouping of ESCCs
Slightly modifying the recently proposed immune-
based cancer classification system by Teng et al. [13], 
ESCCs were stratified into 4 different subgroups based on 
their CD3i status and their amount of PD-L1 positive TCs. 
The resulting four subgroups were the following: subgroup 
1: CD3ihigh / PD-L1high (27/125; 21.6%); subgroup 
2: CD3ilow / PD-L1low (60/125; 48.0%); subgroup 3: 
CD3ilow / PD-L1high (21/125; 16.8%); subgroup 4: 
CD3ihigh / PD-L1low (17/125; 13.6%).
Correlation of immunological factors with each 
other
As highlighted in Table 2, CD3ihigh and CD8ihigh 
cases were each significantly associated with diffuse CD3i/
CD8i distribution (p<0.001, respectively) and PD1ihigh 
- (p<0.001, respectively) as well as PD-L1high tumors 
(CD3: p<0.001; CD8: p=0.005). Additionally, diffusely 
distributed CD3i and CD8i tumors were significantly more 
Figure 1: A. Hematoxylin-Eosin stain of moderately differentiated ESCC; medium and high magnification of an ESCC with low B., C. 
and high D., E. CD3i count; medium and high magnification of an ESCC without F., G. and with high PD-L1 expression H., I..
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Table 1: Association of immunological and clinicopathological factors with survival parameters (univariate).
  Overall Events (OS)
Mean 
overall 
survival 
(SE)
p-value Events (DSS)
Mean disease 
specific survival 
(SE)
p-value Events (DFS)
Mean disease 
free survival 
(SE)
p-value
            
  125 79 76.9 (7.1)  65 89.0 (7.9)  53 86.6 (7.4)  
Age     0.447   0.401   0.710
 median and below 68 45 77.9 (8.9)  36 89.6 (10.0)  33 82.4 (8.7)  
 above median 57 35 57.6 (6.6)  29 65.3 (7.0)  20 77.4 (7.4)  
Sex     0.140   0.067   0.192
 male 95 64 73.1 (8.0) 54 82.3 (8.8) 43 82.4 (8.2)  
 female 30 16 72.4 (8.3)  11 83.7 (8.6)  10 83.8 (8.8)  
pT     <0.001   <0.001  mean DFS not reached 0.002
 1 55 26 106.2 (11.5) 31 119.0 (12.2) 15   
 2 40 36 38.9 (5.5)  29 44.9 (6.5)  25   
 3 28 17 76.8 (13.2)  3 86.8 (14.0)  13   
 4 2 1 36.9 (17.7)  2 36.9 (17.7)  0   
pN     0.012   0.014  mean DFS not reached 0.005
 0 68 38 82.8 (8.6) 42 92.9 (9.2)  24   
 1 47 37 60.7 (9.5)  34 74.0 (11.6)  23   
 2 8 3 63.9 (14.0)  3 63.9 (14.0)  4   
 3 2 2 13.9 (4.8)  2 13.9 (4.8)  2   
pM     0.001   <0.001   <0.001
 0 121 76 79.0 (7.2) 61 91.6 (8.1) 49 89.4 (7.5)  
 1 4 4 6.0 (2.8)  4 14.5 (6.0)  4 8.9 (5.6)  
UICC Stage     0.008   0.002   <0.001
 1 51 21 66.6 (6.8) 19 74.7 (7.2) 23 85.7 (7.2)  
 2 49 24 76.8 (10.1)  24 85.6 (11.0)  25 79.5 (9.7)  
 3 21 37 45.1 (7.9)  34 55.6 (8.8)  36 64.1 (9.6)  
 4 4 4 14.5 (16.0)  4 14.5 (6.0)  4 8.9 (5.6)  
Grade 
(WHO)     0.039   0.071   0.402
 1 6 1 143.2 (19.0) 1 143.2 (19.0) 2 114.2 (24.7)  
 2 61 39 81.2 (9.9)  31 94.3 (11.2)  28 85.2 (9.6)  
 3 58 40 52.5 (6.0)  33 60.1 (6.6)  53 69.6 (7.5)  
CD3i     0.019   0.050   0.009
 low 81 55 62.1 (7.4)  44 73.9 (8.6)  39 78.1 (8.9)  
 high 44 25 96.4 (11.9)  21 106.1 (12.5)  14 104.9 (11.1)  
Distribution 
of CD3i     0.007   0.003   0.004
 focal 75 54 58.3 (7.1)  46 65.5 (7.8)  37 73.4 (8.9)  
 diffuse 50 26 100.1 (11.8)  19 118.7 (12.6)  16 106.5 (11.1)  
CD8i     0.163   0.486   0.185
 low 87 58 73.3 (8.4)  45 90.3 (9.6)  39 81.5 (8.7)  
 high 38 22 83.5 (10.7)  20 88.0 (11.0)  14 100.3 (12.2)  
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frequent in cases with PD1ihigh - (CD3: p<0.001; CD8: 
p=0.014) and PD-L1high tumors (CD3: p<0.001; CD8: 
p=0.003). A high PD1i count was not associated with PD-
L1high tumors. CD3i/CD8i/PD1i count correlated with the 
overall density of TILs of their respective subpopulation 
(CD3: p=0.002; CD8: p<0.001; PD1: p<0.001). Details 
of the correlations of overall TIL density are given in 
Supplementary Table 1.
Correlation of immunological factors with 
clinicopathologic variables
CD3ihigh tumors were significantly associated with 
lower pT stage (p=0.01), lower UICC stage (p=0.001) and 
tumor free local lymph nodes (p=0.001). Cases showing 
a diffuse distribution of CD3is were also more frequent 
in lower pT stage (p=0.02) and lacked nodal involvement 
more often (p=0.03). PD1ihigh tumors showed lower pT 
stage (p=0.015) and frequently lacked nodal involvement 
(p=0.02). CD8ihigh and PD-L1high status, PD-L1 
expression in TILs and PD-L1 copy number status were 
not associated with clinicopathologic variables. Overall 
density of TILs across the tumor area (including TCs and 
tumor stroma) showed no significant associations with 
clinicopathologic features.
Correlation of clinicopathological factors with survival 
parameters
UICC stage (OS: p=0.008; DSS: p=0.002; DFS: 
p<0.001), pT (OS: : p<0.001; DSS: : p<0.001; DFS: 
p=0.002), pN (OS: p=0.012; DSS: p=0.014; DFS: 
p=0.005) and pM (OS: p=0.001; DSS: p<0.001; DFS: 
p<0.001) stadium were all significantly associated with 
survival parameters, while conventional histopathologic 
grade only displayed a comparatively weak association 
with OS (p=0.039), but not with DSS or DFS. Age and 
sex played no role in survival prediction (Table 1). 
Distribution 
of CD8i     0.015   0.080   0.030
 focal 85 60 61.6 (8.0)  47 74.6 (10.3)  40 70.8 (6.9)  
 diffuse 40 20 94.1 (11.0)  18 98.7 (11.1)  13 110.1 (11.7)  
PD1i     0.035   0.117   0.169
 low 84 53 60.6 (7.4)  42 72.2 (8.7)  35 80.8 (9.3)  
 high 41 27 95.5 (12.5)  21 103.2 (13.0)  18 88.9 (9.0)  
PD-L1+ TILs     0.870   0.815   0.844
 low 89 56 77.2 (8.6)  47 87.2 (9.5)  38 82.8 (8.4)  
 high 36 23 69.6 (10.7)  18 84.1 (12.4)  15 96.4 (12.8)  
PD-L1 TCs     0.028   0.006   <0.001
 low/absent 87 54 65.0 (8.8)  47 71.7 (9.7)  42 62.4 (6.8)  
 high 38 26 87.8 (9.1)  18 103.8 (10.6)  11 122.4 (10.6)  
Staining 
intensity of 
PD-L1 
    0.720   0.883   0.293
 weak 30 18 55.9 (8.1)  13 68.2 (9.0)  14 60.9 (9.2)  
 intermediate 31 15 73.9 (11.6)  12 97.9 (14.3)  12 117.6 (13.3)  
 strong 28 20 87.1 (13.3)  17 96.1 (12.8)  8 96.8 (14.2)  
PD-L1 copy 
number status     0.781   0.533   0.951
 Amplification 3 2 25.4 (15.1)  2 25.4 (15.1)  1 37.2 (17.4)  
 Polysomy 19 6 66.2 (10.3)  3 66.2 (10.3)  4 69.2 (11.4)  
 Disomy 92 61 76.5 (8.1)  49 89.2 (9.0)  39 88.5 (8.3)  
 Deletion 10 11 52.5 (10.0)  11 64.4 (10.0)  9 56.5 (11.4)  
CD3i/PD-L1 
subgroups     0.031   0.012   0.001
 low/low 60 44 46.8 (5.3)  38 51.6 (5.8)  33 53.8 (6.3)  
 low/high 21 11 76.9 (7.1)  6 117.4 (16.0)  6 113.9 (16.8)  
 high/high 27 15 86.4 (16.0)  12 100.6 (12.8)  5 130.3 (12.7)  
 high/low 17 10 95.4 (21.4)  9 101.4 (22.0)  9 77.4 (14.7)  
Oncotarget46761www.impactjournals.com/oncotarget
Correlation of immunological factors with survival 
parameters and clinical outcome
As demonstrated in Table 1 and Figure 2, univariate 
analysis revealed that patients with CD3ihigh tumors 
showed favorable OS (p=0.019), DSS (p=0.05) and DFS 
(p=0.009) compared to patients with low CD3is. While 
patients with CD3ihigh tumors displayed a mean OS of 
96.4 months (DSS: 106.1 months; DFS: 104.9 months), 
mean OS (62.1 months) in cases harboring low CD3is 
was significantly shorter (DSS: 73.9 months; DFS: 78.1 
months). Additionally, ESCC-patients with diffusely 
distributed CD3is displayed favorable OS (p=0.007), 
DSS (p=0.003) and DFS (p=0.004) (Figure 2). PD1ihigh 
cancers were associated with favorable OS (p=0.035). 
Pure CD8i count did not show prognostic impact. Overall 
density of TILs across the tumor area (including tumor 
cells and tumor stroma) had no impact on prognosis. As 
highlighted in Figure 3, PD-L1high ESCCs displayed 
improved OS (p=0.028), DSS (p=0.006) and DFS 
(p<0.001), while the extent of PD-L1+ TILs, PD-L1 
staining intensity in TCs and PD-L1 copy number status 
were not associated with survival parameters. Multivariate 
survival analyses (including gender, age, pT, pN) revealed 
improved survival parameters for CD3ihigh tumors 
(OS: p=0.011; DSS: p=0.045; DFS: p=0.004), diffusely 
distributed CD3is (OS: p=0.01; DSS: p=0.005; DFS: 
p=0.009), diffusely distributed CD8is (OS: p=0.005; 
DSS: p=0.03; DFS: p=0.01) and PD-L1high ESCCs 
(OS: p=0.026; DSS: p=0.009; DFS: p=0.001). Details on 
multivariate survival analyses are given in Table 3 and 
Supplementary table 2. 
Additional ESCC subgrouping based on T-cell 
infiltration (CD3i status) and PD-L1 status revealed 
the CD3ilow / PD-L1low subgroup to be significantly 
associated with reduced OS (p=0.031), DSS (p=0.012) and 
DFS (p=0.001) compared to the other subgroups. Mean OS 
(DSS; DFS) of patients with CD3ilow/PD-L1low ESCC 
was 46.8 months (51.6 months; 53.8 months) compared 
to 76.9 months (117.4 months; 113.9 months) for patients 
with CD3ilow / PD-L1high tumors, 86.4 months (100.6 
months; 130.3 months) for patients with CD3ihigh / PD-
L1high cancers and 95.4 months (101.4 months; 77.4 
months) for patients with CD3ihigh / PD-L1low ESCCs 
(Table 1; Figure 4). The observed impact on survival was 
confirmed by a subsequent multivariate analysis including 
age, gender and stage (OS p=0.031; DSS p=0.017; DFS 
p=0.002; Table 3; Supplementary Table 2). 
DISCUSSION
In this study, we analyzed the composition of the IM 
in a comparatively large cohort of 125 primary resected, 
Table 2: Rank-order correlations of intraepithelial lymphocytes with immunological factors in ESCC.
 High CD3i High CD8i Diffuse CD3i Diffuse CD8i High PD1i High PD-L1+ TILs PD-L1 high 
 >20 CD3+ TILs/100 TCs
>13 CD8+ 
TILs/100 TCs   
>6 PD-1+ 
TILs/100 TCs  
>10% PD-
L1+ TCs
High CD3i        
 >20 CD3+ TILs/100 
TCs x r = 0.642 r = 0.595 r = 0.392 r = 0.456 r = 0.091 r = 0.348
  p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.409 p < 0.001
High CD8i        
 >13 CD8+ TILs/100 
TCs  x r = 0.419 r = 0.591 r = 0.442 r = 0.093 r = 0.265
   p < 0.001 p < 0.001 p < 0.001 p = 0.533 p = 0.005
Diffuse CD3i        
   x r = 0.385 r = 0.326 r = 0.09 r = 0.363
    p < 0.001 p < 0.001 p = 0.072 p < 0.001
Diffuse CD8i        
    x r = 0.265 r = 0.056 r = 0.269
     p = 0.014 p = 0.533 p = 0.003
High PD1i        
 >6 PD-1+ TILs/100 
TCs     x r = 0.193 r = 0.170
      p = 0.04 p = 0.081
High PD-L1+ TILs        
      x r = 0.152
       p = 0.1
Oncotarget46762www.impactjournals.com/oncotarget
therapy-naive ESCCs and demonstrate CD3ihigh - as 
well as PD-L1high tumors not only to be significantly 
associated with one another, but also to be independent 
prognosticators of a beneficial ESCC disease course in 
uni- and multivariate statistical analyses. 
Furthermore, an additional, immune-based ESCC 
stratification demarcated a prognostically unfavorable 
subgroup of CD3ilow / PD-L1low cancers.
High densities of CD3+ / CD8+ TILs have been 
associated with improved survival and a favorable disease 
course in various cancers [8-11, 14, 15, 27, 28] and high 
CD3i levels have been identified as strong and independent 
prognosticators for example in human colorectal [14] and 
ovarian cancer [16, 17]. CD3, a transmembranous protein 
virtually exclusive to the T-cell lineage, stains all T-cell 
subgroups, represents the gold standard for the assessment 
of overall T-cell infiltration in daily clinicopathological 
practice [29] and can therefore, in our opinion, be used 
to determine whether a given cancer is in the state of a 
so called “T - cell inflamed microenvironment” or not, 
a condition which has been postulated to be of crucial 
importance for the efficacy of immune checkpoint 
inhibitors [12, 13, 30]. In line with these findings, our 
data show a high count and a diffuse distribution of 
CD3is, but not of overall CD3+ TILs, to be prognostic 
of favorable OS, DSS and DFS in ESCC, suggesting that 
the assessment of CD3is is a comparatively specific and 
standardized approach to evaluate the T-cell mediated 
tumor host relationship, hypothesizing that intraepithelial 
lymphocytes are more likely to truly interact with cancer 
cells than their stromal counterparts. Surprisingly, to our 
knowledge, the prognostic and clinicopathologic influence 
of overall CD3+ TILs and especially of CD3is has not 
yet been studied in ESCC, as the few, and rather loosely 
connected studies regarding TILs in ESCC rather focused 
their efforts on studying potential effects of the PD-1 / PD-
L1 axis [21, 24] or overall CD8+ TILs [21]. Interestingly, 
in contrast to previous work in ESCC [21], neither pure 
CD8i- or overall CD8+ TIL count displayed predictive 
relevance in our cohort, emphasizing that the complex 
interplay between distinctive T-cell subgroups and cancer 
cells is not sufficiently recognized through detection of 
CD8+ TILs alone [31].
Data on expression rates and prognostic value of 
PD-L1 immunohistochemistry in ESCC is rather scarce 
and partially conflicting, as some studies associate PD-
L1 positive ESCC with poor patient outcome [24, 25, 
32], while two recent studies [21, 22] demonstrated 
PD-L1 positivity to be predictive of a rather favorable 
disease course. Pointing in the same direction, our data, 
generated with a robust and highly specific PD-L1 
(SP263) antibody [33] [34-36] in a comparatively large 
Figure 2: Association of CD3ihigh status with improved overall A., disease-specific B. and disease-free C. survival. Correlation of 
diffuse (CD3id) and focal (CD3if) distribution of CD3i on overall D., disease-specific E. and disease-free F. survival.
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Table 3: Multivariate analysis of the impact of CD3i – and PD-L1 status on overall survival.
  HR (OS) lower CI (95%) upper CI (95%) p-value
Gender male 1.000 0.026
 female 0.518 0.290 0.925  
   
Age per year 1.022 0.994 1.051 0.121
pT 1 1.000 <0.001
 2 3.345 1.918 5.834  
 3 1.693 0.875 3.276  
 4 2.068 0.223 19.211  
pN 0 1.000 0.038
 1 1.441 0.879 2.361  
 2 0.554 0.149 2.057  
 3 6.048 1.288 28.387  
CD3i high 1.000 0.011
 low 1.925 1.159 3.200  
  HR (OS) lower CI (95%) upper CI (95%) p-value
Gender male 1.000 0.044
 female 0.551 0.308 0.985  
   
Age per year 1.026 0.997 1.056 0.077
pT 1 1.000 0.001
 2 3.025 1.736 5.272  
 3 1.723 0.893 3.325  
 4 2.962 0.343 25.556  
pN 0 1.000 0.040
 1 1.471 0.892 2.426  
 2 0.602 0.168 2.163  
 3 5.952 1.269 27.904
CD3i diffuse 1.000 0.010
Distribution focal 1.941 1.173 3.210  
  HR (OS) lower CI (95%) upper CI (95%) p-value
Gender male 1.000 0.088
 female 0.597 0.329 1.080  
Age per year 1.022 0.995 1.049 0.112
pT 1 1.000 <0.001
 2 3.415 1.978 5.895  
 3 1.956 1.013 3.777  
 4 5.081 0.529 48.760  
pN 0 1.000 0.048
 1 1.248 0.773 2.014  
 2 0.388 0.105 1.432  
 3 5.210 1.110 24.457  
PD-L1 TCs high 1.000 0.026
 low 1.801 1.074 3.021  
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and extensively investigated, therapy naive tumor series, 
associate PD-L1high ESCC with favorable OS, DSS and 
DFS survival in uni- and multivariate analyses. However, 
comparability between ESCC studies is either hampered 
by small cohort sizes [25], varying PD-L1 antibodies 
and cutoffs, or differences in the amount of investigated 
cancerous tissue [21, 24, 25, 32]. Noteworthy, PD-L1 
copy number analysis revealed PD-L1 amplifications 
to be a far less frequent event in ESCC (2%) than in 
squamous cell carcinoma of the oral cavity (19%) [37], 
indicating an intertumoral spread width regarding the 
biologic mechanisms underlying PD-L1 expression 
between primary squamous cell carcinomas of different 
localizations [38]. Furthermore, PD-L1 staining intensity 
showed no predictive value in our ESCC tumor series.
Besides in ESCC, the association of 
immunohistochemical PD-L1 expression to a beneficial 
outcome has been observed in several entities like 
colorectal carcinoma [39], non-smal cell lung cancer 
[40], melanoma [41], Merkel cell carcinoma [42] or 
breast cancer [43], although the mechanisms underlying 
the observed positive effects remain poorly understood. 
Nevertheless, as PD-L1high ESCC was significantly 
associated with a concurrent CD3ihigh, CD8ihigh and 
PD1ihigh status in our cohort, one might hypothesize 
that high PD-L1 expression in ESCC might rather be 
interpreted as an adaptive mechanism of a given cancer in 
response to an immunoactive tumor-host relationship [41], 
that could therefore contribute to an improved disease 
course and speculatively, to a potential response towards 
immune checkpoint therapy [44]. 
Taking our analyses one step further, we stratified 
our ESCC cohort into four immunogenic subgroups 
based on their PD-L1 / CD3i status. Interestingly, our 
subgrouping approach, which represents a slightly 
adjusted version of the TIL/PD-L1 based cancer 
classification proposed by Teng et al. [13], unmasked a 
comparatively large subgroup of “non-immunogenic”, 
CD3ilow / PD-L1low ESCCs (48% of all tumors), which 
were significantly associated with reduced survival 
parameters in uni- and multivariate analyses, while certain 
tendencies, but no distinct differences in patient survival 
were observed between the other subgroups. Although no 
clear prognostic separation of the CD3ihigh / PD-L1high 
subgroup was visible, we believe that these stratification 
data are concordant with our general findings and with 
those from certain previous studies [21, 22], as they 
prognostically segregate those tumors that show at least 
partial immunoreactivity in a certain manner from those 
who find themselves in a completely “non-immunogenic” 
state. 
Our work has some limitations: (1) our 
investigations were performed on TMA-basis, although 
we examined a substantial number of tumor cores deriving 
Figure 3: Association of PD-L1high status with improved overall A., disease-specific B. and disease-free C. survival.
Figure 4: Decreased overall A., disease specific B. and disease free survival C. of the CD3ilow / PD-L1low ESCC subgroup.
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from the diverse tumor compartments (apical and central 
tumor region, invasive margin). Furthermore (2), only 
resection specimens (3) without postoperative checkpoint 
blockade were investigated. As our work is retrospective in 
nature, our data need to be validated in larger, prospective 
ESCC cohorts as well as on biopsy material. Furthermore, 
the suitability of PD-L1 IHC, intraepithelial CD3+ TILs 
and the subsequent immunologic ESCC subgroups as 
a potential rationale for immune checkpoint therapy 
regimens clearly needs to be investigated by subsequent 
clinical studies in appropriate patient cohorts.
Summarizing, we investigated the contexture of 
ESCCs IM and demonstrate increased intraepithelial 
CD3+ TILs and high PD-L1 expression on tumor cells to 
be independent predictors of a beneficial clinical outcome 
in ESCC. This study not only highlights the comparatively 
frequent expression of PD-L1 in this tumor entity and 
underlines the close association of PD-L1 positive ESCCs 
with increased numbers of intraepithelial T-lymphocytes, 
but also identifies a subset of non-immunogenic ESCCs 
with a distinct clinical course, potentially forming the 
basis for an immune-based stratification in this tumor 
entity.
MATERIALS AND METHODS
Cohort recruitment
Our tumor series comprised 125 ESCC patients, 
who underwent surgical resection between 1994 and 
2007 at Klinikum Rechts der Isar of the Technical 
University of Munich, Germany and at the University 
Hospital Heidelberg, Germany. All tumors were chemo-/
radiation-naive at the time of resection and none of 
the patients received immune checkpoint inhibitors or 
underwent other immune therapy regimens. Only tissue 
from primary tumors was investigated. Hematoxylin-
Eosin (H&E) stained sections were initially reviewed 
by two pathologists (MJ, MB), who confirmed the 
diagnosis of ESCC. Grading and staging of ESCC at 
the time of diagnosis was performed according to the 
current World Health Organization Classification of 
Tumors of the Digestive System [26] and the UICC 
tumor, node, metastasis (TNM) classification [45]. 
Additional clinicopathologic characteristics (sex, age, 
tumor localization, local, nodal / distant relapse) and 
established survival parameters such as overall survival 
(OS), disease-specific survival (DSS) and disease-free 
survival (DFS) were collected for all patients. This study 
has been approved by the Ethics Review Committee of the 
Technical University of Munich (503/16 S).
Tissue microarray construction
Formalin-fixed paraffin-embedded (FFPE) tumor 
samples from the central and apical tumor region as well 
as from the invasive margin were assembled into a tissue 
microarray (TMA) using a Tissue Microarrayer (Beecher 
Instruments, Sun Praierie, USA) with a core size of 0.6 
mm. All samples of a respective tumor region (central/
apical tumor region, invasive margin) were extracted 
from areas harboring a high tumor/stroma ratio. Mean 
tumor cell content per core was 79.3%, ranging from 40% 
- 99 %. Obvious inflammatory hotspots (such as lymph 
follicles or areas of ulceration) were avoided. Considering 
tumor heterogeneity, a minimum of 3 and (where feasible) 
up to 6 tumor cores were taken from the primary tumors 
in areas previously marked by five pathologists (MJ, MB, 
JS, ED, RL). 
Immunohistochemistry
IHC was performed on 2 µm sections from each 
TMA using a PD-L1 primary antibody (VENTANA, 
clone (c): SP-263; dilution (d): 1:100), a PD-1 primary 
antibody (Cell Marque, c: 11RQ-22, d: 1:50) and primary 
antibodies against CD3 (Cell Marque, c: MRQ39, d: 
1:500) and CD8 (DAKO, c: C8/144B, d: 1:50), using an 
automated immunostainer with an iVIEW DAB detection 
kit (Ventana Medical Systems, Roche, Mannheim, 
Germany). 
Scoring of PD-1+, CD3+ and CD8+ tumor 
infiltrating lymphocytes
Scoring of TILs (PD-1+, CD3+, CD8+) was 
performed jointly by two pathologists (MJ, MB) blinded 
to clinicopathological outcome. In general, TILs were 
separately evaluated in every core of the TMA and an 
average score resulting from all cores (and all tumor 
regions) was assigned as the final TIL count for the 
respective case. The analysis of TIL- subpopulations was 
performed in two ways: (1) Scoring of TILs was performed 
in the tumor region of the respective core showing the 
highest density of the particular TIL subpopulation on low 
power magnification (4x). Within this region, the amount 
of intraepithelial CD3+ TILs (CD3i), intraepithelial CD8+ 
TILs (CD8i) and intraepithelial PD-1+ TILs (PD1i) was 
scored manually by counting the quantity of the respective 
lymphocyte subpopulation within tumor cell clusters of 
100 tumor cells using high power magnification (40x). (2) 
In analogy to previous TIL-scoring approaches [46, 47] 
overall density of TILs was evaluated via determination 
of the percent proportion of the tumor area occupied by 
the respective TIL subpopulations. The tumor area was 
defined as tumor cells (TCs) and tumor stroma, while 
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areas of tumor necrosis or inflamed peritumoral areas were 
not taken into account. All corresponding tumor cores of 
each case were analyzed and the average density across 
all cores was calculated. The infiltration pattern of (CD3+/
CD8+) TILs was classified as diffuse, if the respective 
neoplasms showed a continuous intraepithelial infiltration, 
whereas a patchy, discontinuous infiltrate was reported as 
focal.
Immunohistochemical scoring of PD-L1 in tumor 
cells and tumor infiltrating lymphocytes
PD-L1 expression in TCs and in TILs was jointly 
determined by two pathologists (MJ, MB) and was 
evaluated separately in every TMA core before a final 
score resulting from all investigated cores (and all tumor 
regions) was assigned. In TCs, the absolute percentage of 
positive cells was determined. Only membranous staining 
patterns were scored as positive. The intensity of PD-
L1 staining was scored using a 4-tiered grading system 
established in a recent study regarding the efficacy of the 
used PD-L1 SP263 antibody [33], including “no staining” 
(0), “weak staining” (1+), “intermediate staining” (2+) and 
“strong staining” (3+). Immunohistochemical expression 
of PD-L1 in TILs was assessed via a determination of the 
percent proportion of the tumor area occupied by PD-
L1+ TILs, as described previously [47]. Since no obvious 
differences in staining intensity were noted, staining 
intensity of PD-L1 in TILs was not taken into account.
Determination of immunohistochemical scoring 
groups / cut offs
Following the general scoring process, the 
respective data were quantified regarding their respective 
percentile value and patients were stratified into three 
subgroups: lower (below 33. percentile), intermediate (33.-
66. percentile) and upper third (exceeding 66. percentile). 
For further analyses, cases within the upper third were 
classified as “high”, whereas all cases ranging within the 
intermediate or the lower third were classified as “low”. 
PD-L1 Fluorescence in situ Hybridization
FFPE tissue sections (thickness 2µm) of TMAs 
were used for dual-color FISH analysis using a SPEC 
CD274, PDCD1LG2/CEP9 dual color probe and PD-L1 
copy number status (CNS) was evaluated as described 
previously counting at least 20 tumor cell nuclei per tumor 
core [37]. PD-L1 amplification was defined as PD-L1/
CEP9 ratio ≥2.0, with high level amplification defined as 
≥4.0 and low level amplification defined as ≥2.0 and ≤4.0. 
Polysomy 9 was defined as average PD-L1 copy number 
>3 signals/cell. PD-L1 deletion was defined as PD-L1/
CEP9 ratio <0.8.
Statistical analyses
Statistical analyses were performed using SPSS 
23 (SPSS Inc, Chicago, IL, USA). Correlations between 
immunologic characteristics and clinicopathological 
parameters were calculated using Χ2 test and Fisher’s exact 
test. Associations of immunologic factors with each other 
were calculated with Spearman’s rank order correlation. 
Survival probabilities were plotted using the Kaplan-
Meier method and a log-rank test was used to probe 
the significance of differences in survival probabilities. 
Multivariate survival analysis was performed utilizing the 
Cox proportional hazard model. All significances were 
two-sided, p-values ≤0.05 were considered significant.
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